Open Access 01-12-2019 | NSCLC | Study protocol
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
Published in: BMC Cancer | Issue 1/2019
Login to get access